Uvodich ME, Siljander MP, Taunton MJ, et al. - Researchers sought to evaluate the efficacy of low-dose (81 mg) and regular-strength (325 mg) aspirin (ASA) for venous thromboembolism (VTE) chemoprophylaxis in primary total hip arthroplasties (THAs) and total knee arthroplasties (TKAs). A total of 3,512 primary TJAs (2344 THAs and 1168 TKAs) with ASA used as VTE chemoprophylaxis were identified. ASA was administered to patients twice daily for 4-6 weeks after surgery with 961 (27%) receiving low-dose ASA and 2,551 (73%) receiving regular-strength ASA. VTE was identified at cumulative incidence of < 1% at 90 days. Although this study is underpowered, it seems that effectiveness of twice daily low-dose ASA is equivalent to that of twice daily regular-strength ASA for VTE chemoprophylaxis, with no difference in risk of GI bleeds or mortality.